Algorithmiq, founded in 2020 and headquartered in Finland, is pioneering the integration of quantum computing into the life sciences sector. With the slogan, "We develop advanced quantum algorithms to solve complex problems in life sciences," the company is positioned at the intersection of Biotechnology, Life Sciences, and Quantum industries. Their mission emphasizes revolutionizing life sciences by harnessing quantum technology to tackle problems currently beyond the reach of classical computing. By blending expertise in quantum information, complex systems, and computational physics, Algorithmiq is at the forefront of discovering new drugs and developing new materials.
Recently, the company secured a €14.00M Series A investment on June 27, 2023. This funding round was backed by prominent investors such as Presidio Ventures, Tesi, Thames Trust, Inventure, and the European Investment Bank, underscoring significant industry confidence in their innovative approach and potential market impact.